Bavarian Nordic closed its first quarter with growth on the top line though negative results in operations and on the bottom line have also increased significantly.
The company is advancing in spite of waning sales from the vaccines Rabipur/Rabavert for rabies and Encepur for tick-borne encephalitis.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.